Home » Stocks » AKRO

Akero Therapeutics, Inc. (AKRO)

Stock Price: $29.89 USD -0.29 (-0.96%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $29.60 -0.29 (-0.97%) Jan 21, 4:52 PM
Market Cap 1.04B
Revenue (ttm) n/a
Net Income (ttm) -65.11M
Shares Out 34.00M
EPS (ttm) -2.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $29.89
Previous Close $30.18
Change ($) -0.29
Change (%) -0.96%
Day's Open 30.29
Day's Range 29.39 - 30.70
Day's Volume 147,253
52-Week Range 12.80 - 39.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

SAN FRANCISCO--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohep...

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoh...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presi...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medici...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medici...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicin...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients ...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medic...

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc.

PRNewsWire - 5 months ago

SAN FRANCISCO, Aug. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc.

Benzinga - 6 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, PSTX, AZZ, GSK, NKTX, PRSP, TSE, WCC
PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medici...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 7, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicin...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 6, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicin...

24/7 Wall Street - 6 months ago

Akero Therapeutics Inc. (NASDAQ: AKRO) has only been public for about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can ...

Investors Business Daily - 6 months ago

Akero Therapeutics charged up Wednesday after the biotech company unveiled promising results for a hepatitis treatment.

Zacks Investment Research - 6 months ago

Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its P...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including bio...

Zacks Investment Research - 7 months ago

Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 7 months ago

Is (AKRO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Akero Therapeutics, Inc. (AKRO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medici...

The Motley Fool - 7 months ago

If you haven't heard of Akero Therapeutics before, take note. Its NASH drug candidate could be a game changer.

Zacks Investment Research - 7 months ago

Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicin...

Zacks Investment Research - 8 months ago

Akero Therapeutics Inc (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 9 months ago

Akero Therapeutics: A Very Attractive Risk/Reward Opportunity

Zacks Investment Research - 9 months ago

Akero Therapeutics, Inc. (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 9 months ago

Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

The Motley Fool - 9 months ago

A first-in-class new drug candidate for the treatment of non-alcoholic steatohepatitis produced some compelling clinical trial results.

Zacks Investment Research - 10 months ago

Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GuruFocus - 1 year ago

On Dec. 17, GuruFocus reported that in a July article, Kiplinger identified Morphic Holding Inc.

Other stocks mentioned: DERM, GBT, MRNA
Benzinga - 1 year ago

Akero Therapeutics shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16.

About AKRO

Akero Therapeutics, a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Industry
Biotechnology
IPO Date
Jun 20, 2019
CEO
Dr. Andrew Cheng
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
AKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is 60.29, which is an increase of 101.71% from the latest price.

Price Target
$60.29
(101.71% upside)
Analyst Consensus: Strong Buy